Pre-made Rovalpituzumab Tesirine benchmark antibody (Whole mAb ADC, anti-DLL3 therapeutic antibody, Anti-SCDO1 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-made Rovalpituzumab Tesirine benchmark antibody (Whole mAb ADC, anti-DLL3 therapeutic antibody, Anti-SCDO1 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Rovalpituzumab tesirine (Rova-T) is an experimental antibody-drug conjugate targeting the protein DLL3 on tumor cells.[1][2] It was originally developed by Stemcentrx and was purchased by AbbVie.[3] It was tested for use in small-cell lung cancer, but development was terminated after unsuccessful phase III trial.[4][5]

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-980-1mg	1mg	Inquiry
GMP-Bios-INN-980-10mg	10mg	Inquiry
GMP-Bios-INN-980-100mg	100mg	Inquiry
GMP-Bios-INN-980-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Rovalpituzumab Tesirine Biosimilar, Whole Mab Adc, Anti-Dll3 Antibody: Anti-SCDO1 therapeutic antibody Drug Conjugate
INN Name	Rovalpituzumab Tesirine
Target	DLL3
Format	Whole mAb ADC
Derivation	Humanized
Species Reactivity	human
CH1 Isotype	IgG1 - kappa
VD LC	IgG1 - kappa
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Stemcentrx, Inc. (San Francisco CA USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0